Condition
BRAF V600 Mutation clinical trials and research
As of November 12, 2026, Find a Trial lists 5 BRAF V600 Mutation clinical trials that are recruiting, at sites in 10 countries (most in China (3), United States (3), Australia (1)). By phase: Phase 2 (2), Phase 1/2 (1), Early Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 10Countries
Newest BRAF V600 Mutation clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Dabrafenib and trametinib dose-reduction for BRAF V600 low-grade glioma | Phase 2 | Birmingham, Alabama and 11 other locations | Recruiting | Aug 7, 2025 |
| Treatment for patients with BRAFV600E mutant metastatic colorectal cancer | — | Shanghai, Shanghai Municipality | Recruiting | Dec 27, 2024 |
| Neoadjuvant immunotherapy for localized non-small cell lung cancer with rare mutations | Phase 2 | Guanzhou, Guangdong | Recruiting | Apr 5, 2023 |
| Evaluating BDTX-4933 for patients with specific cancer mutations | Phase 1/2 | Gilbert, Arizona and 48 other locations | Recruiting | Mar 28, 2023 |
| Adjuvant therapy for melanoma based on treatment response | Early Phase 1 | Tampa, Florida | Recruiting | Feb 5, 2021 |
All recruiting trials (5)
-
Dabrafenib and trametinib dose-reduction for BRAF V600 low-grade glioma
This trial tries to see if stopping or slowly lowering dabrafenib and trametinib after about 12–24 months works for people with BRAF V600–mutant low-grade glioma.
-
Treatment for patients with BRAFV600E mutant metastatic colorectal cancer
This study looks at how well current treatments work for patients in China with advanced colorectal cancer that has a specific BRAFV600E mutation.
-
Neoadjuvant immunotherapy for localized non-small cell lung cancer with rare mutations
This study is testing if a combination of a new immunotherapy drug and chemotherapy can help people with localized lung cancer that has rare mutations by seeing if it can completely eliminate the tumor.
-
Evaluating BDTX-4933 for patients with specific cancer mutations
This study is testing a new drug called BDTX-4933 to see if it can help adults with advanced cancers that have certain gene mutations feel better and improve their treatment options.
-
Adjuvant therapy for melanoma based on treatment response
This study tests if a combination of new medications can help people with melanoma who have a specific gene mutation stay cancer-free after their initial treatment.
Related topics
Quick answers
How many BRAF V600 Mutation clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 10 countries. The most sites are in China (3 trials), United States (3 trials), Australia (1 trial), Denmark (1 trial), France (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2, Phase 1/2: 1, Early Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.